Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival

Human Pathology

Volumn 43, Issue 4, 2012, Pages 496-505

  Brenne, Kjersti ^a   Nymoen, Dag André ^a   Hetland, Thea Eline ^a   Trope', Claes G ^a,b   Davidson, Ben ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Diagnosis; Malignant mesothelioma; Ovarian carcinoma; Quantitative real time PCR; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EHF; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; EFFUSION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858155270     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.05.023     Document Type: Article

References (36)

1. T. Oikawa, and T. Yamada Molecular biology of the Ets family of transcription factors Gene 303 2003 11 34 (Pubitemid 36151767)
2. T. Oikawa ETS transcription factors: possible targets for cancer therapy Cancer Sci 95 2004 626 633 (Pubitemid 39255808)
3. A. Seth, and D.K. Watson ETS transcription factors and their emerging roles in human cancer Eur J Cancer 41 2005 2462 2478 (Pubitemid 41540623)
4. T. Hsu, M. Trojanowska, and D.K. Watson Ets proteins in biological control and cancer J Cell Biochem 91 2004 896 903
5. V.I. Sementchenko, and D.K. Watson Ets target genes: past, present and future Oncogene 19 2000 6533 6548 (Pubitemid 32108443)
6. J. Dittmer The biology of the Ets 1 proto-oncogene Mol Cancer 2 2003 29
7. V. Laudet, C. Hanni, and D. Stehelin Molecular phylogeny of the ETS gene family Oncogene 18 1999 1351 1359 (Pubitemid 29094887)
8. K. Kas, E. Finger, and F. Grall ESE-3, a novel member of an epithelium-specific Ets transcription factor subfamily, demonstrates different target gene specificity from ESE-1 J Biol Chem 275 2000 2986 2998 (Pubitemid 30082077)
9. American Cancer Society Cancer facts and figures 2010. Estimated new cancers cases and deaths by sex for all sites Available at: http://www.cancer. org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures- 2010 (Accessed July 31, 2010)
10. B. Davidson Malignant effusions: from diagnosis to biology Diagn Cytopathol 31 2004 246 254 (Pubitemid 39314820)
11. B. Davidson Biological characteristics of cancers involving the serosal cavities Crit Rev Oncog 13 2007 189 227 (Pubitemid 351239093)
12. B. Davidson, Z. Zhang, and L. Kleinberg Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma Clin Cancer Res 12 2006 5944 5950 (Pubitemid 44703753)
13. E. Beillard, N. Pallisgaard, and V.H. van der Velden Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase reaction (RQ-PCR)-a Europe against cancer program Leukemia 17 2003 2474 2486 (Pubitemid 38072587)
14. A.M. Marchevsky Application of immunohistochemistry to the diagnosis of malignant mesothelioma Arch Pathol Lad Med 132 2008 397 401 (Pubitemid 351328814)
15. N.G. Ordóñez Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update Adv Anat Pathol 13 2006 16 25 (Pubitemid 44357145)
16. N.G. Ordóñez What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update Hum Pathol 38 2007 1 16 (Pubitemid 44880219)
17. S. Suster, and C.A. Moran Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma Adv Anat Pathol 13 2006 316 329 (Pubitemid 44673447)
18. P.A. Fetsch, and A. Abati Immunocytochemistry in effusion cytology Cancer 93 2001 293 308
19. B. Davidson, S. Nielsen, and J. Christensen The role of desmin and N-cadherin in effusion cytology Am J Surg Pathol 25 2001 1405 1412
20. A.V. Bassarova, J.M. Nesland, and B. Davidson D2-40 is not a specific marker for cells of mesothelial origin in serous effusions Am J Surg Pathol 30 2006 878 882 (Pubitemid 44264979)
21. J. He, Y. Pan, and J. Hu Profile of ETS gene expression in human breast carcinoma Cancer Biol Ther 6 2007 76 82 (Pubitemid 46294180)
22. C.K. Galang, W.J. Mullers, and G. Foos Changes in the expression of many ETS family transcription factors and of potential target genes in normal mammary tissue and tumors J Biol Chem 19 2004 11281 11292 (Pubitemid 38401625)
23. S.E. Hufton, P.T. Moerkerk, and R. Brandtwijk A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization FEBS Lett 463 1999 77 82 (Pubitemid 30001722)
24. R. Cangemi, A. Mensah, and V. Albertini Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer Oncogene 27 2008 2877 2885 (Pubitemid 351620453)
25. H.E. Gonzalez, M. Gujrati, and M. Frederick Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg 129 2003 754 759 (Pubitemid 36858964)
26. Y. Yuan, D.A. Nymoen, and H.P. Dong Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions Hum Pathol 40 2009 1453 1460
27. Y. Yuan, D.A. Nymoen, and H.T. Stavnes Tenascin-X is a novel diagnostic marker of malignant mesothelioma Am J Surg Pathol 33 2009 1673 1682
28. B. Davidson Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma Curr Cancer Drug Targets 7 2007 109 120 (Pubitemid 46345512)
29. B. Davidson, V. Espina, and A.M. Steinberg Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling Clin Cancer Res 12 2006 791 799 (Pubitemid 43259859)
30. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
31. G.D. Aletti, M.D. Gallenberg, and W.A. Cliby Current management strategies for ovarian cancer Mayo Clin Proc 82 2007 751 770 (Pubitemid 46878099)
32. W.I. Hoskins, W.P. McGuire, and M.F. Brady The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979
33. P.G. Rose, S. Nerenstone, and M.F. Brady Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2004 2489 2546
34. B. Davidson, R. Reich, and I. Goldberg Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma Clin Cancer Res 7 2001 551 557 (Pubitemid 32707977)
35. B. Davidson, I. Goldberg, and W.H. Gotlieb PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma Clin Cancer Res 9 2003 1412 1419 (Pubitemid 36418395)
36. B. Davidson, B. Risberg, and I. Goldberg Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome Am J Surg Pathol 25 2001 1493 1500 (Pubitemid 33096963)